52 related articles for article (PubMed ID: 7976352)
1. [Synthesis of N-(4-carbomethoxy-4-phthalimidobutanoyl)-N-substituted glycines, proline and pyroglutamic acid].
Lin WQ; Cai CY; Gong KS; Wu Y; Long Z; Luo XX; Yang L; Li JF; Yao XJ
Yao Xue Xue Bao; 1994; 29(5):346-54. PubMed ID: 7976352
[TBL] [Abstract][Full Text] [Related]
2. [Synthesis of N-(4-carbethoxy-4-substituted butyryl)-N-substituted glycines].
Chen YM; Cai CY; Gong KS
Yao Xue Xue Bao; 1989; 24(12):887-94. PubMed ID: 2486235
[TBL] [Abstract][Full Text] [Related]
3. [Synthesis of N-(4-substituted amino-4-oxobutyryl)-N-substituted glycines].
Wu Y; Cai CY; Gong KS
Yao Xue Xue Bao; 1992; 27(9):717-20. PubMed ID: 1293947
[TBL] [Abstract][Full Text] [Related]
4. [Synthesis and biological activity of some Val(Ala)-Tyr and Val-Tyr-Tyr peptides].
Chen PL; Peng SX; Yang ZX
Yao Xue Xue Bao; 1992; 27(12):895-902. PubMed ID: 1299138
[TBL] [Abstract][Full Text] [Related]
5. The synthesis and angiotensin converting enzyme (ACE) inhibitory activity of chalcones and their pyrazole derivatives.
Bonesi M; Loizzo MR; Statti GA; Michel S; Tillequin F; Menichini F
Bioorg Med Chem Lett; 2010 Mar; 20(6):1990-3. PubMed ID: 20167484
[TBL] [Abstract][Full Text] [Related]
6. [Synthesis of N-(2-mercaptobenzoyl)-N-(alkyl/aryl)-glycines and corresponding disulfides].
Chen PL; Yang ZX; Peng SX
Yao Xue Xue Bao; 1987 Sep; 22(9):662-70. PubMed ID: 3445757
[No Abstract] [Full Text] [Related]
7. Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
Fink CA; Carlson JE; McTaggart PA; Qiao Y; Webb R; Chatelain R; Jeng AY; Trapani AJ
J Med Chem; 1996 Aug; 39(16):3158-68. PubMed ID: 8759637
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the slow pressor effect of angiotensin II contributes to the antihypertensive effect of angiotensin-converting enzyme inhibitors in renovascular hypertension.
Melaragno MG; Fink GD
J Pharmacol Exp Ther; 1996 Jul; 278(1):297-303. PubMed ID: 8764363
[TBL] [Abstract][Full Text] [Related]
9. Reversal of the suppressed kidney renin level in the hypertensive transgenic rat TGR(mRen-2)27 by angiotensin converting enzyme inhibition.
Tokita Y; Franco-Saenz R; Mulrow PJ
Am J Hypertens; 1995 Oct; 8(10 Pt 1):1031-9. PubMed ID: 8845072
[TBL] [Abstract][Full Text] [Related]
10. Do the cardiovascular effects of angiotensin-converting enzyme (ACE) I involve ACE-independent mechanisms? new insights from proline-rich peptides of Bothrops jararaca.
Ianzer D; Santos RA; Etelvino GM; Xavier CH; de Almeida Santos J; Mendes EP; Machado LT; Prezoto BC; Dive V; de Camargo AC
J Pharmacol Exp Ther; 2007 Aug; 322(2):795-805. PubMed ID: 17475904
[TBL] [Abstract][Full Text] [Related]
11. [Biochemical and physiological activity of new peptide inhibitors of angiotensin-converting enzyme].
Gomazkov OA; Pozdnev VF; Kalinina EV; Komissarova NV; Medvedeva NA; Nesterova MA; Petriĭ OP
Biull Eksp Biol Med; 1996 Sep; 122(9):279-81. PubMed ID: 8974479
[No Abstract] [Full Text] [Related]
12. Effect of cadmium and captopril on serum angiotensin converting enzyme activity in rats.
Puri VN
Indian Heart J; 1997; 49(3):297-9. PubMed ID: 9291654
[TBL] [Abstract][Full Text] [Related]
13. The hypotensive mechanisms for the aqueous stem bark extract of Musanga cecropioides in Sprague-Dawley rats.
Adeneye AA; Ajagbonna OP; Mojiminiyi FB; Odigie IP; Ojobor PD; Etarrh RR; Adeneye AK
J Ethnopharmacol; 2006 Jun; 106(2):203-7. PubMed ID: 16442759
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats.
De Gennaro Colonna V; Rigamonti A; Fioretti S; Bonomo S; Manfredi B; Ferrario P; Bianchi M; Berti F; Muller EE; Rossoni G
Eur J Pharmacol; 2005 Jun; 516(3):253-9. PubMed ID: 15963975
[TBL] [Abstract][Full Text] [Related]
15. General pharmacology of the non-sulfhydryl angiotensin converting enzyme inhibitor N-[8-amino-1(S)-carboxyoctyl]-L-alanyl-L-proline.
Shirota M; Hayashi M; Kajiwara Y; Kitabatake K; Uruno T; Kubota K
Arzneimittelforschung; 1993 Nov; 43(11):1169-74. PubMed ID: 8292059
[TBL] [Abstract][Full Text] [Related]
16. Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors.
Coric P; Turcaud S; Meudal H; Roques BP; Fournie-Zaluski MC
J Med Chem; 1996 Mar; 39(6):1210-9. PubMed ID: 8632427
[TBL] [Abstract][Full Text] [Related]
17. Antihypertensive effect of an angiotensin converting enzyme inhibitory peptide from enzyme modified cheese.
Tonouchi H; Suzuki M; Uchida M; Oda M
J Dairy Res; 2008 Aug; 75(3):284-90. PubMed ID: 18620614
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship study between Ornithyl-Proline and Lysyl-Proline based tripeptidomimics as angiotensin-converting enzyme inhibitors.
Pavar MC; Hanif K; Azam A; Lata S; Qadar Pasha MA; Pasha S
Bioorg Med Chem Lett; 2006 Apr; 16(8):2117-21. PubMed ID: 16464585
[TBL] [Abstract][Full Text] [Related]
19. Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action.
Fournie-Zaluski MC; Coric P; Thery V; Gonzalez W; Meudal H; Turcaud S; Michel JB; Roques BP
J Med Chem; 1996 Jun; 39(13):2594-608. PubMed ID: 8691458
[TBL] [Abstract][Full Text] [Related]
20. Dual metalloprotease inhibitors. 6. Incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors.
Robl JA; Cimarusti MP; Simpkins LM; Brown B; Ryono DE; Bird JE; Asaad MM; Schaeffer TR; Trippodo NC
J Med Chem; 1996 Jan; 39(2):494-502. PubMed ID: 8558518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
